Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Franziska Duckstein
Observed names:
Duckstein, Franziska,
F. Duckstein
Institutions:
Medizinische Hochschule Brandenburg Theodor Fontane,
Universitätsklinikum Brandenburg an der Havel
Observed institutions:
University of Potsdam,
Medizinische Hochschule Brandenburg Theodor Fontane,
Universitätsklinikum Brandenburg an der Havel,
Brandenburg University of Technology Cottbus-Senftenberg
ORCID:
0000-0002-0938-8502
Observed ORCID:
0000-0002-0938-8502
OpenAlex ID:
A5012903423
Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score
2022
·
Jochen G. Mainz
, Carlos Zagoya
, et al.
·
Frontiers in Pharmacology
·
81
PDF
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER study
2023
·
Jochen G. Mainz
, Karen Lester
, et al.
·
Journal of Cystic Fibrosis
·
45
Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid
2021
·
Jochen G. Mainz
, Christin Arnold
, et al.
·
Frontiers in Immunology
·
35
PDF
Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis
2023
·
L.R. Caley
, C. Zagoya
, et al.
·
Journal of Cystic Fibrosis
·
16
PDF
Diagnosing constipation in patients with cystic fibrosis applying ESPGHAN criteria
2021
·
Marina Abib Stefano
, Natascha Silva Sandy
, et al.
·
Journal of Cystic Fibrosis
·
14
Scoring Abdominal Symptoms in People with Cystic Fibrosis
2024
·
Harold Tabori
, Anton Barucha
, et al.
·
Journal of Clinical Medicine
·
9
PDF
Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage
2022
·
Nina Erdmann
, Theresa Schilling
, et al.
·
Frontiers in Immunology
·
9
PDF
The potential of volatile organic compound analysis for pathogen detection and disease monitoring in patients with cystic fibrosis
2022
·
Anton Barucha
, Renan M. Mauch
, et al.
·
Expert Review of Respiratory Medicine
·
8
Dynamics of abdominal symptoms during the start of a new therapy with elexacaftor/tezacaftor/ivacaftor using the novel CFAbd-day2day questionnaire
2023
·
Jochen G. Mainz
, Anton Barucha
, et al.
·
Frontiers in Pharmacology
·
7
PDF
The novel CFAbd-Score.kidⒸ reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor – first results
2025
·
Jochen G. Mainz
, Pauline Sadrieh
, et al.
·
Journal of Cystic Fibrosis
·
5
PDF
Validation of the CFAbd-Score.kidⒸ, a Novel gastrointestinal patient reported outcome measure, specific for children with cystic fibrosis
2025
·
Pauline Sadrieh
, Lilith Bechinger
, et al.
·
Journal of Cystic Fibrosis
·
4
PDF
Would it have happened without Christmas? Thoracic emphysema and allergic bronchopulmonary aspergillosis in a juvenile cystic fibrosis patient with the G551D mutation receiving ivacaftor
2021
·
Jochen G. Mainz
, Nina Erdmann
, et al.
·
ERJ Open Research
·
3
PDF
Cross-cultural adaptation and validation of the CFAbd-Score for gastrointestinal symptoms in patients with cystic fibrosis
2024
·
Flávia N.S. Infante
, Elizete A. Lomazi
, et al.
·
Jornal de Pediatria
·
2
Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score
2023
·
Jochen G. Mainz
, Carlos Zagoya
, et al.
·
Frontiers in Pharmacology
·
2
PDF
Audit of sweat chloride testing reveals analytical errors
2021
·
Freerk Prenzel
, Uta Ceglarek
, et al.
·
Clinical Chemistry and Laboratory Medicine (CCLM)
·
2
The validated French CFAbd‐Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor
2025
·
Isabelle Sermet‐Gaudelus
, Pauline Sadrieh
, et al.
·
Journal of Pediatric Gastroenterology and Nutrition
·
1
PDF
Chronic rhinosinusitis in people with CF, a rapidly changing field
2024
·
Jochen G. Mainz
, Franziska Duckstein
, et al.
·
Journal of Cystic Fibrosis
·
1
Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients
2026
·
Jochen G. Mainz
, Vivien Greiner
, et al.
·
Pediatric Pulmonology
PDF
Improvement of abdominal symptoms in people with Cystic Fibrosis during therapy with Elexacaftor/Tezacaftor/Ivacaftor brings gastrointestinal involvement into the paediatric pulmonologistʼs focus
2025
·
Pauline Sadrieh
, Lutz Nährlich
, et al.
·
Klinische Pädiatrie
P279 Associations between changes in CFAbd-Score, dietary intake and weight following elexacaftor/tezacaftor/ivacaftor (ETI) therapy: preliminary analysis
2024
·
L. Caley
, C. Zagoya
, et al.
·
Journal of Cystic Fibrosis
EPS6.07 Longitudinal impact of elexacaftor/tezacaftor/ivacaftor on abdominal symptoms assessed with the CFAbd-Score and on intestinal inflammation in people with cystic fibrosis aged ≥ 12 years – The RECOVER study
2023
·
J.G. Mainz
, K. Lester
, et al.
·
Journal of Cystic Fibrosis
PDF
Show more works
View as search
Works count:
22
Citation count:
244
H-index:
8
I10-index:
5
Year
Topic
Type